https://www.biospace.com/intersect-ent-reports-preliminary-fourth-quarter-and-full-year-2018-revenue
Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue - BioSpace
Jan 7, 2019 - Revenue for the full year 2018 is expected to be in the range of $108.3 to $108.5 million, an increase of 12-13% compared to $96.3 million for 2017
intersect entfourth quarter
https://www.biospace.com/intersect-ent-to-report-third-quarter-2019-financial-results
Intersect ENT to Report Third Quarter 2019 Financial Results - BioSpace
Oct 18, 2019 - The company expects to issue the release at approximately 7:30 a.m. ET and management will host a conference call at 8:00 a.m. ET.
2019 financial resultsintersect entthird quarterreport
https://www.annualreports.com/Company/Intersect-ENT-Inc
Intersect ENT Inc - AnnualReports.com
intersect entinc
https://www.biospace.com/intersect-ent-to-report-third-quarter-2017-financial-results
Intersect ENT To Report Third Quarter 2017 Financial Results - BioSpace
Oct 17, 2017 - Intersect ENT, Inc. today announced that it will release financial results for its third quarter on November 2, 2017.
intersect entthird quarterfinancial resultsreport2017
https://www.businesswire.com/news/home/20211102006202/en/Intersect-ENT-Reports-Third-Quarter-2021-Financial-Results
Intersect ENT Reports Third Quarter 2021 Financial Results
Intersect ENT Reports Third Quarter 2021 Financial Results
intersect entthird quarter2021 financialreportsresults
https://www.fool.com/earnings/call-transcripts/2019/02/25/intersect-ent-inc-xent-q4-2018-earnings-conference.aspx
Intersect ENT Inc (XENT) Q4 2018 Earnings Conference Call Transcript | The Motley Fool
Apr 15, 2019 - XENT earnings call for the period ending December 31, 2018.
https://www.biospace.com/intersect-ent-announces-publication-of-a-pooled-analysis-of-the-sinuva-sinus-implant-for-nasal-polyps
Intersect ENT Announces Publication of a Pooled Analysis of the SINUVA Sinus Implant for Nasal...
Jun 5, 2019 - Pooled analysis of the RESOLVE and RESOLVE II Studies Provides Level 1a Clinical Evidence
https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-intersect-ent-inc-301351224.html
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors...